Dr. Ingrid Gause-Nilsson is Senior Medical Lead at AstraZeneca R&D, Global Medicine Development, Gothenburg, Sweden. In her current role she is medical responsible within AstraZeneca for the ongoing CVOT DECLARE. The study is evaluating the effect of dapagliflozin, a SGLT2 inhibitor approved for treatment of type 2 diabetes, on cardiovascular outcomes and include more than 17,000 patients with either established cardiovascular disease or multiple cardiovascular risk factors.
Dr Gause-Nilsson received her MD from Gothenburg University and got her Ph D in Endocrine Physiology doing research on hormonal effects on adipose tissue metabolism. Her clinical training is in Geriatric Medicine and she is Associate Professor at Gothenburg University. During her clinical training at the Department of Geriatric Medicine she did research in epidemiology and was involved in population studies in the elderly in Sweden and in the Nordic countries. Additionally she developed a special interest in osteoporosis research and was involved in epidemiological studies and was investigator in several clinical trials mainly on bisphosphonates.
After joining Astra in 1998 she continued in the field of metabolic research on insulin resistance and type 2 diabetes, particularly on PPAR agonists. During her years in the pharmaceutical industry she has worked with several compounds with different mode of actions in development for type 2 diabetes. She has conducted studies in all phases, from phase 1 to cardiovascular outcome studies, and has gained a wide experience in protocol and study designs, conducting global studies and collecting and evaluating data in clinical trials.